Hikma shares fall as sales falter

HIKMA Pharmaceuticals’ shares fell 10.5pc after the drug maker lowered its forecast sales for this year.

The FTSE 250 firm – which is pinning its hopes on a potential blockbuster

generic inhaler product to

rival GSK’S asthma drug

Advair in the US – said revenues from its second-biggest division, generics, will be $620m (£482m). This com- pared to a $800m estimate in April. Shares closed down 139p at £11.90.